<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867412465022</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867412465022</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Khoraminya</surname><given-names>Nayereh</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412465022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tehrani-Doost</surname><given-names>Mehdi</given-names></name>
<xref ref-type="aff" rid="aff2-0004867412465022">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jazayeri</surname><given-names>Shima</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412465022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hosseini</surname><given-names>Aghafateme</given-names></name>
<xref ref-type="aff" rid="aff3-0004867412465022">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Djazayery</surname><given-names>Abolghassem</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412465022">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0004867412465022"><label>1</label>Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</aff>
<aff id="aff2-0004867412465022"><label>2</label>Roozbeh Psychiatry Hospital, Department of Psychiatry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran</aff>
<aff id="aff3-0004867412465022"><label>3</label>Department of Statistics, School of Health Management and Medical Information Sciences, Tehran University of Medical Sciences, Tehran, Iran</aff>
<author-notes>
<corresp id="corresp1-0004867412465022">Shima Jazayeri, #60 Alvand Street, Argantin Square, Tehran, Iran. Email: <email>sh_jazayeri@tums.ac.ir</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>3</issue>
<fpage>271</fpage>
<lpage>275</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0004867412465022">
<title>Objective:</title>
<p>To compare the therapeutic effects of vitamin D<sub>3</sub> plus fluoxetine and fluoxetine alone in patients with major depressive disorder.</p>
</sec>
<sec id="section2-0004867412465022">
<title>Methods:</title>
<p>In the present double-blind, randomized, placebo-controlled trial, 42 patients with a diagnosis of major depressive disorder based on DSM-IV criteria were randomly assigned into two groups to receive daily either 1500 IU vitamin D<sub>3</sub> plus 20 mg fluoxetine or fluoxetine alone for 8 weeks. Depression severity was assessed at 2-week intervals using the 24-item Hamilton Depression Rating Scale (HDRS) as a primary outcome measure and the 21-item Beck Depression Inventory (BDI) as a secondary outcome measure. Serum 25(OH) vitamin D was measured at baseline and after intervention.</p>
</sec>
<sec id="section3-0004867412465022">
<title>Results:</title>
<p>Forty patients completed the trial. A two-way repeated-measures analysis of variance showed that depression severity based on HDRS and BDI decreased significantly after intervention, with a significant difference between the two groups. The vitamin D + fluoxetine combination was significantly better than fluoxetine alone from the fourth week of treatment.</p>
</sec>
<sec id="section4-0004867412465022">
<title>Conclusions:</title>
<p>In the present 8-week trial, the vitamin D + fluoxetine combination was superior to fluoxetine alone in controlling depressive symptoms.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Fluoxetine</kwd>
<kwd>major depressive disorder</kwd>
<kwd>vitamin D</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-0004867412465022" sec-type="intro">
<title>Introduction</title>
<p>Unipolar depressive disorders were the third cause of disability-adjusted life years lost in all age groups based on a World Health Organization report of the year 2004 and, if the current trend continues, it is anticipated to be the leading cause of morbidity by 2030 (<xref ref-type="bibr" rid="bibr35-0004867412465022">WHO, 2008</xref>).</p>
<p>It is reported that about 19–34% of major depressive disorder cases resist good response to routine antidepressants (<xref ref-type="bibr" rid="bibr2-0004867412465022">Arroll et al., 2005</xref>; <xref ref-type="bibr" rid="bibr11-0004867412465022">Fava and Davidson, 1996</xref>).</p>
<p>Considering the wide use of complementary and alternative medications such as dietary supplements in depressed patients and our insufficient knowledge about the interaction between drugs and supplements, investigating the subject from a clinical point of view seems important (<xref ref-type="bibr" rid="bibr22-0004867412465022">Kessler et al., 2001</xref>).</p>
<p>Vitamin D receptors exist in many different tissues; thus, hypovitaminosis D theoretically can cause various adverse effects on health (<xref ref-type="bibr" rid="bibr15-0004867412465022">Holick, 2007</xref>). Recently, growing evidence has linked this vitamin to brain function (<xref ref-type="bibr" rid="bibr26-0004867412465022">McGrath et al., 2001</xref>). Active target sites have been identified for this nutrient in different parts of the brain, such as the cortex and hippocampus (<xref ref-type="bibr" rid="bibr21-0004867412465022">Kalueff and Tuohimaa, 2007</xref>; <xref ref-type="bibr" rid="bibr24-0004867412465022">Langub et al., 2001</xref>). Moreover, the main enzyme responsible for changing vitamin D to its active form exists in the brain (<xref ref-type="bibr" rid="bibr10-0004867412465022">Eyles et al., 2005</xref>; <xref ref-type="bibr" rid="bibr30-0004867412465022">Neveu et al., 1994</xref>). Finally, animal studies have confirmed the fundamental role of vitamin D in the development of the brain (<xref ref-type="bibr" rid="bibr9-0004867412465022">Eyles et al., 2009</xref>).</p>
<p>Some information about the relationship of this vitamin with psychiatric diseases in humans was derived from studies showing worse cognitive performance in age-related hypovitaminosis D (<xref ref-type="bibr" rid="bibr4-0004867412465022">Buell and Dawson-Hughes, 2008</xref>; <xref ref-type="bibr" rid="bibr5-0004867412465022">Cherniack et al., 2009</xref>) and accelerated osteoporosis or less bone mineral density in psychiatric patients (<xref ref-type="bibr" rid="bibr8-0004867412465022">Eskandari et al., 2007</xref>; <xref ref-type="bibr" rid="bibr13-0004867412465022">Halbreich and Palter, 1996</xref>; <xref ref-type="bibr" rid="bibr28-0004867412465022">Michelson et al., 1996</xref>). Furthermore, cross-sectional studies have shown that there is an inverse association between vitamin D status and depressive symptoms (<xref ref-type="bibr" rid="bibr1-0004867412465022">Armstrong et al., 2007</xref>; <xref ref-type="bibr" rid="bibr16-0004867412465022">Hoogendijk et al., 2008</xref>; <xref ref-type="bibr" rid="bibr19-0004867412465022">Jorde et al., 2008</xref>; <xref ref-type="bibr" rid="bibr29-0004867412465022">Nanri et al., 2009</xref>; <xref ref-type="bibr" rid="bibr31-0004867412465022">Oren et al., 1994</xref>; <xref ref-type="bibr" rid="bibr33-0004867412465022">Schneider et al., 2000</xref>; <xref ref-type="bibr" rid="bibr34-0004867412465022">Stewart and Hirani, 2010</xref>; <xref ref-type="bibr" rid="bibr36-0004867412465022">Wilkins et al., 2006</xref>). Also, a large cross-sectional and prospective study in women aged 50–79 years has shown that higher intakes of vitamin D were associated with lower depressive symptoms and a lower risk of depressive symptoms after 3 years (<xref ref-type="bibr" rid="bibr3-0004867412465022">Bertone-Johnson et al., 2011</xref>). Few interventional studies have assessed the effects of vitamin D supplementation on mood and depression symptoms in healthy (<xref ref-type="bibr" rid="bibr25-0004867412465022">Lansdowne and Provost, 1998</xref>), overweight and obese subjects (<xref ref-type="bibr" rid="bibr19-0004867412465022">Jorde et al., 2008</xref>), or in patients with seasonal affective disorder (<xref ref-type="bibr" rid="bibr12-0004867412465022">Gloth et al., 1999</xref>) or normal women (<xref ref-type="bibr" rid="bibr14-0004867412465022">Harris and Dawson-Hughes, 1993</xref>). The results have been inconsistent, which may be due to the doses of vitamin D given, different rates of prevalence of vitamin D deficiency, or clinical depression in the participants. We could not find any published randomized, placebo-controlled clinical trial about vitamin D supplementation in major depressive disorder. A recent open trial by <xref ref-type="bibr" rid="bibr37-0004867412465022">Zanetidou and colleagues (2011)</xref> has shown that a single high dose of vitamin D had beneficial effects in elderly patients with major depressive disorder.</p>
<p>Taking into account the potential therapeutic role of vitamin D in mood disorders, we designed the present study to determine the therapeutic effects of vitamin D as an adjunctive therapy to fluoxetine in patients with major depressive disorder. As low doses of vitamin D had not been effective in previous studies (<xref ref-type="bibr" rid="bibr7-0004867412465022">Dumville et al., 2006</xref>; <xref ref-type="bibr" rid="bibr14-0004867412465022">Harris and Dawson-Hughes, 1993</xref>), we chose a dose of 1500 IU/day, which was greater than the recommended dietary allowance (RDA) and lower than the upper tolerable intake level (UL) for this vitamin (<xref ref-type="bibr" rid="bibr18-0004867412465022">Institute of Medicine, 2010</xref>).</p>
</sec>
<sec id="section6-0004867412465022" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section7-0004867412465022">
<title>Patients</title>
<p>The patients were 42 outpatients aged between 18 and 65 years old with a diagnosis of major depressive disorder without psychotic features based on DSM-IV criteria and with a score of ≥ 15 on the 17-item Hamilton Depression Rating Scale (HDRS) who were referred from Roozbeh Psychiatry Hospital, Tehran University of Medical Sciences, Tehran. The patients had not taken any antidepressant or dietary supplements during the previous 2 months, were free from other psychiatric diagnoses, significant medical illnesses or suicidal thoughts and were willing to participate in the study. Substance abuse, pregnancy and lactation, and the occurrence of important adverse effects from medications were exclusion criteria.</p>
</sec>
<sec id="section8-0004867412465022">
<title>Test drugs</title>
<p>Tablets of 1000 IU vitamin D<sub>3</sub> were supplied by Merk (Germany). The placebo tablets contained starch, were identical to the vitamin D<sub>3</sub> tablets in appearance and were supplied by SOHA Pharmaceutical Company (Iran). Fluoxetine was provided as 20 mg capsules.</p>
</sec>
<sec id="section9-0004867412465022">
<title>Trial design</title>
<p>After signing written informed consent, eligible patients were randomly assigned to two groups to receive daily either 1.5 tablets (1500 IU) of vitamin D<sub>3</sub> plus one capsule (20 mg) fluoxetine or vitamin D placebo plus 20 mg fluoxetine for 8 weeks in a double-blind, placebo-controlled manner. Depression severity was assessed at 2-week intervals using the 24-item HDRS as a primary outcome measure and the 21-item Beck Depression Inventory (BDI) as a secondary outcome measure.</p>
<p>Blood samples were collected after 8–10 hours of fasting at baseline and serums were frozen at −80°C to measure 25(OH)D levels by enzyme-linked immunosorbent assay (ELISA).</p>
<p>The protocol of the study was compliant with the declaration of Helsinki and was approved by the Ethical Committee of Tehran University of Medical Sciences. The trial was registered in Iran Registry of Clinical Trials (IRCT ID: IRCT201201072394N6).</p>
<p>Compliance was measured by counting fluoxetine pills and measuring serum 25(OH)D.</p>
</sec></sec>
<sec id="section10-0004867412465022" sec-type="results">
<title>Results</title>
<p>Sampling was started in November 2010 and the last subject entered the study in October 2011. Analysis was performed on the 40 patients who completed the study. One patient was lost to follow-up from the fourth week of treatment in the fluoxetine group and one was excluded from the fluoxetine + vitamin D group because of severe anxiety at week 2. No other important adverse effect was reported. The baseline characteristics of patients are shown in <xref ref-type="table" rid="table1-0004867412465022">Table 1</xref>. There were no significant differences between the two groups with regard to age, weight, body mass index (BMI), serum 25(OH)D, sex, use of sunscreen, smoking status or depression severity. Moreover, the BMI did not change significantly during the intervention period (<italic>p</italic> &gt; 0.05).</p>
<table-wrap id="table1-0004867412465022" position="float">
<label>Table1.</label>
<caption>
<p>General characteristics of the patients.</p>
</caption>
<graphic alternate-form-of="table1-0004867412465022" xlink:href="10.1177_0004867412465022-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Fluoxetine<break/>(<italic>n</italic> = 20)</th>
<th align="left">Fluoxetine + vitamin D<break/>(<italic>n</italic> = 20)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>39.65 ± 8.27</td>
<td>38.1 ± 10.07</td>
<td>0.598<xref ref-type="table-fn" rid="table-fn2-0004867412465022">a</xref></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>75.13 ± 16.62</td>
<td>73.08 ± 15.33</td>
<td>0.687<xref ref-type="table-fn" rid="table-fn2-0004867412465022">a</xref></td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>29.00 ± 6.82</td>
<td>28.32 ± 5.43</td>
<td>0.728<xref ref-type="table-fn" rid="table-fn2-0004867412465022">a</xref></td>
</tr>
<tr>
<td>Serum 25(OH)D (ng/ml)</td>
<td>23.05 ± 4.42</td>
<td>23.55 ± 4.03</td>
<td>0.714<xref ref-type="table-fn" rid="table-fn2-0004867412465022">a</xref></td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>3/17</td>
<td>3/17</td>
<td>1.000<xref ref-type="table-fn" rid="table-fn3-0004867412465022">b</xref></td>
</tr>
<tr>
<td>Use of sunscreen (yes/no)</td>
<td>10/10</td>
<td>8/12</td>
<td>0.525<xref ref-type="table-fn" rid="table-fn3-0004867412465022">b</xref></td>
</tr>
<tr>
<td>Smoking (yes/no)</td>
<td>4/16</td>
<td>5/15</td>
<td>1.000<xref ref-type="table-fn" rid="table-fn3-0004867412465022">b</xref></td>
</tr>
<tr>
<td>HDRS (score)</td>
<td>30.2 ± 5.83</td>
<td>29.4 ± 5.23</td>
<td>0.651<xref ref-type="table-fn" rid="table-fn2-0004867412465022">a</xref></td>
</tr>
<tr>
<td>BDI (score)</td>
<td>31.65 ± 7.33</td>
<td>32.45 ± 7.35</td>
<td>0.733<xref ref-type="table-fn" rid="table-fn2-0004867412465022">b</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0004867412465022"><p>BMI: body mass index; HDRS: Hamilton Depression Rating Scale; BDI: Beck Depression Inventory.</p></fn>
<fn id="table-fn2-0004867412465022"><label>a:</label><p>Independent sample t-test</p></fn>
<fn id="table-fn3-0004867412465022"><label>b:</label><p>Chi square test</p></fn>
</table-wrap-foot></table-wrap>
<p>With regard to compliance, all patients consumed more than 90% of the fluoxetine tablets and the serum 25(OH)D increased significantly in the fluoxetine + vitamin D group from 23.55 ± 4.03 to 46.85 ± 14.14 (<italic>p</italic> &lt; 0.001). There was a negative correlation between baseline serum 25(OH)D and depression severity (<xref ref-type="fig" rid="fig1-0004867412465022">Figure 1</xref>).</p>
<fig id="fig1-0004867412465022" position="float">
<label>Figure 1.</label>
<caption>
<p>Correlation between vitamin D status and depression severity (HDRS: Hamilton Depression Rating Scale).</p>
</caption>
<graphic xlink:href="10.1177_0004867412465022-fig1.tif"/></fig>
<p>As <xref ref-type="table" rid="table2-0004867412465022">Table 2</xref> shows, the two-way repeated-measures analysis of variance showed that depression severity decreased significantly after intervention with a significant difference between the two groups. Analysis of covariance for depression severity adjusted for baseline values at weeks 2, 4, 6 and 8 showed that the vitamin D–fluoxetine combination was significantly better than fluoxetine alone from the fourth week of treatment.</p>
<table-wrap id="table2-0004867412465022" position="float">
<label>Table 2.</label>
<caption>
<p>Depression severity during 8 weeks of intervention.</p>
</caption>
<graphic alternate-form-of="table2-0004867412465022" xlink:href="10.1177_0004867412465022-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="left" colspan="2">Time<sup><xref ref-type="table-fn" rid="table-fn5-0004867412465022">a</xref></sup></th>
<th align="left" colspan="2">Time and group<sup><xref ref-type="table-fn" rid="table-fn5-0004867412465022">a</xref></sup> interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression severity</td>
<td>Study group</td>
<td>Week 0</td>
<td>Week 2</td>
<td>Week 4<sup><xref ref-type="table-fn" rid="table-fn6-0004867412465022">b</xref></sup></td>
<td>Week 6<sup><xref ref-type="table-fn" rid="table-fn6-0004867412465022">b</xref></sup></td>
<td>Week 8<sup><xref ref-type="table-fn" rid="table-fn6-0004867412465022">b</xref></sup></td>
<td><italic>F</italic></td>
<td><italic>p</italic>-value</td>
<td><italic>F</italic></td>
<td><italic>p</italic>-value</td>
</tr>
<tr>
<td rowspan="2">HDRS (score)</td>
<td>Fluoxetine</td>
<td>30.2 ± 5.83</td>
<td>25.23 ± 4.60</td>
<td>21.35 ± 3.63</td>
<td>19.00 ± 3.37</td>
<td>17.2 ± 4.16</td>
<td>9.29</td>
<td>0.004</td>
<td>8.54</td>
<td>0.006</td>
</tr>
<tr>
<td>Fluoxetine + vitamin D</td>
<td>29.4 ± 5.23</td>
<td>23.94 ± 4.49</td>
<td>18.5 ± 3.76</td>
<td>14.6 ± 4.17</td>
<td>11.7 ± 4.60</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">BDI (score)</td>
<td>Fluoxetine</td>
<td>31.65 ± 7.33</td>
<td>29.17 ± 6.78</td>
<td>25.18 ± 6.93</td>
<td>21.00 ± 6.81</td>
<td>17.95 ± 6.31</td>
<td>2.24</td>
<td>&lt; 0.001</td>
<td>6.72</td>
<td>0.013</td>
</tr>
<tr>
<td>Fluoxetine + vitamin D</td>
<td>32.45 ± 7.35</td>
<td>27.73 ± 7.50</td>
<td>20.44 ± 6.56</td>
<td>16.73 ± 8.11</td>
<td>13.2 ± 8.64</td>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0004867412465022"><p>Data are shown as mean ± SD.</p></fn>
<fn id="table-fn5-0004867412465022">
<label>a</label>
<p>Repeated measure analysis of variance was done.</p></fn>
<fn id="table-fn6-0004867412465022">
<label>b</label>
<p>Analysis of covariance adjusted for baseline values showed that there was a significant difference between the two intervention groups (<italic>p</italic>-value &lt; 0.05).</p></fn>
<fn id="table-fn7-0004867412465022"><p>HDRS: Hamilton Depression Rating Scale; BDI: Beck Depression Inventory.</p></fn>
</table-wrap-foot></table-wrap>
</sec>
<sec id="section11-0004867412465022" sec-type="discussion">
<title>Discussion</title>
<p>To our knowledge, the present study is the first randomized, placebo-controlled trial specifically designed to determine the effects of vitamin D supplementation in patients with major depressive disorder, and the results showed that vitamin D is safe and effective as an adjunctive treatment to fluoxetine in major depressive disorder. It should be considered that 95% of patients participating in the study were vitamin D-deficient based on serum 25(OH)D concentrations &lt; 30 ng/ml and were moderately or severely depressed.</p>
<p>The few previous studies assessing the effects of vitamin D supplementation on mood and depression symptoms have shown inconsistent results. Some of them have reported positive effects of supplementation in overweight and obese people (<xref ref-type="bibr" rid="bibr19-0004867412465022">Jorde et al., 2008</xref>), patients with seasonal affective disorder (<xref ref-type="bibr" rid="bibr12-0004867412465022">Gloth et al., 1999</xref>) and healthy subjects (<xref ref-type="bibr" rid="bibr25-0004867412465022">Lansdowne and Provost, 1998</xref>), but other results were not consistent to ours, which may be due to inadequate doses of vitamin D (<xref ref-type="bibr" rid="bibr14-0004867412465022">Harris and Dawson-Hughes, 1993</xref>), a low prevalence of vitamin D deficiency (<xref ref-type="bibr" rid="bibr6-0004867412465022">Dean et al., 2011</xref>) and a low prevalence of clinical depression, or seasonal affective disorder (<xref ref-type="bibr" rid="bibr7-0004867412465022">Dumville et al., 2006</xref>) in the participants. Moreover, in a recent open trial, it was shown that a single 300,000 IU dose of vitamin D could decrease depression severity in elderly patients with major depression (<xref ref-type="bibr" rid="bibr37-0004867412465022">Zanetidou et al., 2011</xref>). However, a large randomized trial in older women has shown that a single annual dose of 500,000 IU of vitamin D<sub>3</sub> for 3–5 years had no benefit on mood, although there was a non-significant improvement in those taking medications for anxiety and depression (<xref ref-type="bibr" rid="bibr32-0004867412465022">Sanders et al., 2011</xref>). In another study, 40,000 IU per week of vitamin D for 6 months in people with low levels of serum 25(OH)D had no significant effect on depressive symptom scores compared to placebo (<xref ref-type="bibr" rid="bibr23-0004867412465022">Kjaergaard et al., 2012</xref>). The daily doses of vitamin D used in these studies were too high compared to the UL and probably the relationship between serum vitamin D and depression is not linear as it is between neonatal blood vitamin D and risk of schizophrenia (<xref ref-type="bibr" rid="bibr27-0004867412465022">McGrath et al., 2010</xref>).</p>
<p>An inverse linear correlation was also seen between depression severity and serum 25(OH)D levels in our study. Some previous studies have also reported an association between depression status and lower levels of serum vitamin D metabolites (<xref ref-type="bibr" rid="bibr16-0004867412465022">Hoogendijk et al., 2008</xref>; <xref ref-type="bibr" rid="bibr20-0004867412465022">Jorde et al., 2006</xref>; <xref ref-type="bibr" rid="bibr33-0004867412465022">Schneider et al., 2000</xref>; <xref ref-type="bibr" rid="bibr36-0004867412465022">Wilkins et al., 2006</xref>).</p>
<p>The mechanism of action of vitamin D in the brain and its effects on mood is not completely understood. A possible mechanism is an increased expression of the tyrosine hydroxylase gene (the rate-limiting enzyme of the catecholamine synthesis pathway) and enhancement of the bioavailability of some neurotransmitters such as dopamine, noradrenalin and adrenalin by vitamin D. This vitamin may also affect the cholinergic system by activating choline acetyltransferase, which is considered to play a role in the pathophysiology of mood disorders. Moreover, it was shown that calcitriol potentially can enhance the level of neurotrophic factors involved in depression such as nerve growth factor (NGF), glial-derived neurotrophic factor (GDNF) and neurotrophin 3 (NT-3) (<xref ref-type="bibr" rid="bibr17-0004867412465022">Humble, 2010</xref>).</p>
<p>In conclusion, it seems that vitamin D deficiency has a role in the pathophysiology of depression and that its dietary supplementation is safe and effective as an adjunctive treatment in major depressive disorder, at least in vitamin D-deficient subjects.</p>
</sec>
</body>
<back>
<ack>
<p>This work was supported by the Vice-Chancellor for Research, Tehran University of Medical Sciences, Tehran, Iran. We would also like to acknowledge the cooperation and help of Dr Farhoud, Dr Nejatisafa and Dr Arbabi. Thanks are also extended to SOHA Pharmaceutical Company for supplying placebo tablets.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of interest</label>
<p>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>DJ</given-names></name>
<name><surname>Meenagh</surname><given-names>GK</given-names></name>
<name><surname>Bickle</surname><given-names>I</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Vitamin D deficiency is associated with anxiety and depression in fibromyalgia</article-title>. <source>Clinical Rheumatology</source> <volume>26</volume>: <fpage>551</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr2-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arroll</surname><given-names>B</given-names></name>
<name><surname>Macgillivray</surname><given-names>S</given-names></name>
<name><surname>Ogston</surname><given-names>S</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis</article-title>. <source>Annals of Family Medicine</source> <volume>3</volume>: <fpage>449</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr3-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bertone-Johnson</surname><given-names>ER</given-names></name>
<name><surname>Powers</surname><given-names>SI</given-names></name>
<name><surname>Spangler</surname><given-names>L</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Vitamin D intake from foods and supplements and depressive symptoms in a diverse population of older women</article-title>. <source>American Journal of Clinical Nutrition</source> <volume>94</volume>: <fpage>1104</fpage>–<lpage>1112</lpage>.</citation>
</ref>
<ref id="bibr4-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buell</surname><given-names>JS</given-names></name>
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
</person-group> (<year>2008</year>) <article-title>Vitamin D and neurocognitive dysfunction: Preventing ‘D’ecline?</article-title> <source>Molecular Aspects of Medicine</source> <volume>29</volume>: <fpage>415</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr5-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cherniack</surname><given-names>EP</given-names></name>
<name><surname>Troen</surname><given-names>BR</given-names></name>
<name><surname>Florez</surname><given-names>HJ</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Some new food for thought: The role of vitamin D in the mental health of older adults</article-title>. <source>Current Psychiatry Reports</source> <volume>11</volume>: <fpage>12</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr6-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dean</surname><given-names>AJ</given-names></name>
<name><surname>Bellgrove</surname><given-names>MA</given-names></name>
<name><surname>Hall</surname><given-names>T</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Effects of vitamin D supplementation on cognitive and emotional functioning in young adults – A randomised controlled trial</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e25966</fpage>.</citation>
</ref>
<ref id="bibr7-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dumville</surname><given-names>JC</given-names></name>
<name><surname>Miles</surname><given-names>JNV</given-names></name>
<name><surname>Porthouse</surname><given-names>J</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women</article-title>. <source>Journal of Nutrition, Health and Aging</source> <volume>10</volume>: <fpage>151</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr8-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eskandari</surname><given-names>F</given-names></name>
<name><surname>Martinez</surname><given-names>PE</given-names></name>
<name><surname>Torvik</surname><given-names>S</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Low bone mass in premenopausal women with depression</article-title>. <source>Archives of Internal Medicine</source> <volume>167</volume>: <fpage>2329</fpage>–<lpage>2336</lpage>.</citation>
</ref>
<ref id="bibr9-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eyles</surname><given-names>DW</given-names></name>
<name><surname>Feron</surname><given-names>F</given-names></name>
<name><surname>Cui</surname><given-names>X</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Developmental vitamin D deficiency causes abnormal brain development</article-title>. <source>Psychoneuroendocrinology</source> <volume>34</volume>: <fpage>S247</fpage>–<lpage>S257</lpage>.</citation>
</ref>
<ref id="bibr10-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eyles</surname><given-names>DW</given-names></name>
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Kinobe</surname><given-names>R</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Distribution of the vitamin D receptor and 1α-hydroxylase in human brain</article-title>. <source>Journal of Chemical Neuroanatomy</source> <volume>29</volume>: <fpage>21</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr11-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fava</surname><given-names>M</given-names></name>
<name><surname>Davidson</surname><given-names>KG</given-names></name>
</person-group> (<year>1996</year>) <article-title>Definition and epidemiology of treatment-resistant depression</article-title>. <source>Psychiatric Clinics of North America</source> <volume>19</volume>: <fpage>179</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr12-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gloth</surname><given-names>FM</given-names></name>
<name><surname>Alam</surname><given-names>W</given-names></name>
<name><surname>Hollis</surname><given-names>B</given-names></name>
</person-group> (<year>1999</year>) <article-title>Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder</article-title>. <source>Journal of Nutrition, Health and Aging</source> <volume>3</volume>: <fpage>5</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr13-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halbreich</surname><given-names>U</given-names></name>
<name><surname>Palter</surname><given-names>S</given-names></name>
</person-group> (<year>1996</year>) <article-title>Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes</article-title>. <source>Schizophrenia Bulletin</source> <volume>22</volume>: <fpage>447</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr14-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harris</surname><given-names>S</given-names></name>
<name><surname>Dawson-Hughes</surname><given-names>B</given-names></name>
</person-group> (<year>1993</year>) <article-title>Seasonal mood changes in 250 normal women</article-title>. <source>Psychiatry Research</source> <volume>49</volume>: <fpage>77</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr15-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holick</surname><given-names>MF</given-names></name>
</person-group> (<year>2007</year>) <article-title>Medical progress: Vitamin D deficiency</article-title>. <source>New England Journal of Medicine</source> <volume>357</volume>: <fpage>266</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr16-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoogendijk</surname><given-names>WJG</given-names></name>
<name><surname>Lips</surname><given-names>P</given-names></name>
<name><surname>Dik</surname><given-names>MG</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults</article-title>. <source>Archives of General Psychiatry</source> <volume>65</volume>: <fpage>508</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr17-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humble</surname><given-names>MB</given-names></name>
</person-group> (<year>2010</year>) <article-title>Vitamin D, light and mental health</article-title>. <source>Journal of Photochemistry and Photobiology B: Biology</source> <volume>101</volume>: <fpage>142</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr18-0004867412465022">
<citation citation-type="book">
<collab>Institute of Medicine</collab> (<year>2010</year>) <article-title>Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine</article-title>. <source>Dietary Reference Intakes for Calcium and Vitamin D</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academy Press</publisher-name>, <year>2010</year>.</citation></ref>
<ref id="bibr19-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jorde</surname><given-names>R</given-names></name>
<name><surname>Sneve</surname><given-names>M</given-names></name>
<name><surname>Figenschau</surname><given-names>Y</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: Randomized double blind trial</article-title>. <source>Journal of Internal Medicine</source> <volume>264</volume>: <fpage>599</fpage>–<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr20-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jorde</surname><given-names>R</given-names></name>
<name><surname>Waterloo</surname><given-names>K</given-names></name>
<name><surname>Saleh</surname><given-names>F</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels: The Tromsø study</article-title>. <source>Journal of Neurology</source> <volume>253</volume>: <fpage>464</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr21-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalueff</surname><given-names>AV</given-names></name>
<name><surname>Tuohimaa</surname><given-names>P</given-names></name>
</person-group> (<year>2007</year>) <article-title>Neurosteroid hormone vitamin D and its utility in clinical nutrition</article-title>. <source>Current Opinion in Clinical Nutrition and Metabolic Care</source> <volume>10</volume>: <fpage>12</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr22-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>Davis</surname><given-names>RB</given-names></name>
<name><surname>Foster</surname><given-names>DF</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Long-term trends in the use of complementary and alternative medical therapies in the United States</article-title>. <source>Annals of Internal Medicine</source> <volume>135</volume>: <fpage>262</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr23-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjaergaard</surname><given-names>M</given-names></name>
<name><surname>Waterloo</surname><given-names>K</given-names></name>
<name><surname>Wang</surname><given-names>CE</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: Nested case-control study and randomised clinical trial</article-title>. <source>British Journal of Psychiatry</source> Epub ahead of print <day>12</day> <month>July</month> <year>2012</year>.</citation>
</ref>
<ref id="bibr24-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langub</surname><given-names>MC</given-names></name>
<name><surname>Herman</surname><given-names>JP</given-names></name>
<name><surname>Malluche</surname><given-names>HH</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Evidence of functional vitamin D receptors in rat hippocampus</article-title>. <source>Neuroscience</source> <volume>104</volume>: <fpage>49</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr25-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lansdowne</surname><given-names>ATG</given-names></name>
<name><surname>Provost</surname><given-names>SC</given-names></name>
</person-group> (<year>1998</year>) <article-title>Vitamin D3 enhances mood in healthy subjects during winter</article-title>. <source>Psychopharmacology</source> <volume>135</volume>: <fpage>319</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr26-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McGrath</surname><given-names>J</given-names></name>
<name><surname>Feron</surname><given-names>F</given-names></name>
<name><surname>Eyles</surname><given-names>D</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Vitamin D: The neglected neurosteroid?</article-title> <source>Trends in Neurosciences</source> <volume>24</volume>: <fpage>570</fpage>–<lpage>572</lpage>.</citation>
</ref>
<ref id="bibr27-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McGrath</surname><given-names>JJ</given-names></name>
<name><surname>Eyles</surname><given-names>DW</given-names></name>
<name><surname>Pedersen</surname><given-names>CB</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Neonatal vitamin D status and risk of schizophrenia: A population-based case-control study</article-title>. <source>Archives of General Psychiatry</source> <volume>67</volume>: <fpage>889</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr28-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michelson</surname><given-names>D</given-names></name>
<name><surname>Stratakis</surname><given-names>C</given-names></name>
<name><surname>Hill</surname><given-names>L</given-names></name>
<etal/></person-group>. (<year>1996</year>) <article-title>Bone mineral density in women with depression</article-title>. <source>New England Journal of Medicine</source> <volume>335</volume>: <fpage>1176</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr29-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nanri</surname><given-names>A</given-names></name>
<name><surname>Mizoue</surname><given-names>T</given-names></name>
<name><surname>Matsushita</surname><given-names>Y</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: Analysis by survey season</article-title>. <source>European Journal of Clinical Nutrition</source> <volume>63</volume>: <fpage>1444</fpage>–<lpage>1447</lpage>.</citation>
</ref>
<ref id="bibr30-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neveu</surname><given-names>I</given-names></name>
<name><surname>Naveilhan</surname><given-names>P</given-names></name>
<name><surname>Menaa</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>1994</year>) <article-title>Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro</article-title>. <source>Journal of Neuroscience Research</source> <volume>38</volume>: <fpage>214</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr31-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oren</surname><given-names>DA</given-names></name>
<name><surname>Schulkin</surname><given-names>J</given-names></name>
<name><surname>Rosenthal</surname><given-names>NE</given-names></name>
</person-group> (<year>1994</year>) <article-title>1,25 (OH)2 vitamin D3 levels in seasonal affective disorder: Effects of light</article-title>. <source>Psychopharmacology</source> <volume>116</volume>: <fpage>515</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr32-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanders</surname><given-names>KM</given-names></name>
<name><surname>Stuart</surname><given-names>AL</given-names></name>
<name><surname>Williamson</surname><given-names>EJ</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Annual high-dose vitamin D3 and mental well-being: Randomised controlled trial</article-title>. <source>British Journal of Psychiatry</source> <volume>198</volume>: <fpage>357</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr33-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>B</given-names></name>
<name><surname>Weber</surname><given-names>B</given-names></name>
<name><surname>Frensch</surname><given-names>A</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Vitamin D in schizophrenia, major depression and alcoholism</article-title>. <source>Journal of Neural Transmission</source> <volume>107</volume>: <fpage>839</fpage>–<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr34-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>R</given-names></name>
<name><surname>Hirani</surname><given-names>V</given-names></name>
</person-group> (<year>2010</year>) <article-title>Relationship between vitamin D levels and depressive symptoms in older residents from a national survey population</article-title>. <source>Psychosomatic Medicine</source> <volume>72</volume>: <fpage>608</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr35-0004867412465022">
<citation citation-type="book"><collab>WHO</collab> (<year>2008</year>) <source>The Global Burden of Diseases: 2004 update</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</citation>
</ref>
<ref id="bibr36-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilkins</surname><given-names>CH</given-names></name>
<name><surname>Sheline</surname><given-names>YI</given-names></name>
<name><surname>Roe</surname><given-names>CM</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults</article-title>. <source>American Journal of Geriatric Psychiatry</source> <volume>14</volume>: <fpage>1032</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr37-0004867412465022">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zanetidou</surname><given-names>S</given-names></name>
<name><surname>Murri</surname><given-names>MB</given-names></name>
<name><surname>Buffa</surname><given-names>A</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Vitamin D supplements in geriatric major depression</article-title>. <source>International Journal of Geriatric Psychiatry</source> <volume>26</volume>: <fpage>1209</fpage>–<lpage>1210</lpage>.</citation>
</ref></ref-list>
</back>
</article>